Gastroenterology billing
Most billing problems are caused by describing an encounter incorrectly. Gastroenterology has one caused by the encounter genuinely changing: a screening colonoscopy in which a polyp is found and removed is no longer a screening, and the patient who was told the procedure was free now has cost-sharing. Whether they are protected from it depends on a two-character modifier that records the procedure's original intent.
- A screening colonoscopy that finds and treats a polyp becomes a diagnostic or therapeutic service
- Modifier PT is what tells the payer the procedure began as a screening
- Screening frequency, and eligibility from age 45, are set by regulation rather than by the practice
- Only the more extensive endoscopic procedure is reported for a single encounter
This is an educational guide to how billing works for gastroenterology — its workflow, coding, and payer considerations. It is general information, not a statement that US Medical Billing serves this specialty, and not billing, coding, or legal advice.
What makes gastroenterology billing distinct
Colorectal cancer screening is the specialty's defining billing problem, and it is a problem about intent rather than technique. Medicare's screening colonoscopy codes are G0105 for an individual at high risk and G0121 for one who is not, with G0104 for screening flexible sigmoidoscopy. If the endoscopist finds a polyp and removes it, the service delivered is no longer the service that was scheduled, and the claim moves to the diagnostic or therapeutic code that describes what was actually done. The patient's financial position moves with it.
Congress addressed that directly. Section 122 of Division CC of the Consolidated Appropriations Act, 2021 amended section 1833(a) of the Social Security Act to create a special coinsurance rule for exactly this situation. Where modifier PT is submitted on a claim line to indicate that a screening colorectal procedure -- G0104, G0105 or G0121 -- has become a diagnostic or therapeutic service, the deductible is waived and the coinsurance is reduced, on a schedule that phases the reduction down until, for services furnished on or after the start of 2030, no coinsurance applies at all. The modifier is not a formality. It is the mechanism by which a patient keeps the benefit of having come in for a screening.
Coverage itself is defined in regulation, not in a payer's discretion. 42 CFR 410.37 sets out which procedures count as colorectal cancer screening tests, including screening colonoscopies and the anesthesia furnished in conjunction with them, and fixes the intervals -- broadly, a longer interval for an individual not at high risk and a much shorter one for an individual who is, with defined interactions between colonoscopy and flexible sigmoidoscopy. Since the CY 2023 Physician Fee Schedule final rule, the definition also reaches a follow-on screening colonoscopy performed after a covered non-invasive stool-based test returns a positive result: CMS had historically treated that colonoscopy as diagnostic, and now treats the pair as one complete colorectal cancer screening.
How gastroenterology billing flows
A gastroenterology revenue cycle runs on scheduled procedures, which makes almost all of its risk front-loadable -- and makes the failure to front-load it expensive.
Scheduling with intent recorded
The order records whether the procedure is a screening, a surveillance examination in a patient with a personal or family history, or a diagnostic procedure prompted by symptoms. That distinction is what modifier PT later depends on, and it cannot be reconstructed from the operative note alone.
Common operational challenges
The recurring difficulties are all versions of one thing: a fact established before the procedure has to survive into the claim.
Carrying intent from the order to the claim
Whether the procedure was scheduled as a screening is decided weeks earlier, in a different system, by a different person. If that fact does not travel, modifier PT is not appended and the patient pays cost-sharing Congress intended to protect them from.
Tracking screening intervals and risk status
Eligibility depends on how long it has been since the last screening of each type and on whether the record supports high-risk status. Both are historical facts the practice may not hold, and both decide coverage.
Explaining a bill for a free procedure
A patient who came in for a preventive screening and left with a polypectomy did not consent to a bill. Handling that well is a pre-procedure disclosure problem, and handling it badly is the specialty's most common patient complaint.
Professional, facility and anesthesia claims in step
One procedure can generate three claims from three billing entities. When they disagree about whether the service was a screening, the payer's adjudication of each will disagree too.
Documentation and coding considerations
Endoscopic coding rewards a note that states what was found, what was done, and where each specimen came from. The CPT code set is maintained by the American Medical Association; the notes below describe documentation considerations rather than reproduce any code descriptions.
Screening codes and the risk distinction
Medicare reports screening colonoscopy as G0105 for an individual at high risk and G0121 for one who is not, and screening flexible sigmoidoscopy as G0104. High-risk status has a regulatory definition in 42 CFR 410.37 -- close relatives with colorectal cancer or adenomatous polyps, defined family syndromes, a personal history of polyps or cancer, or inflammatory bowel disease -- and it changes both the code and the interval.
Modifier PT
PT indicates that a colorectal cancer screening test has become a diagnostic or therapeutic service. Appended to a line on a claim carrying the diagnostic or therapeutic code, it triggers the waived deductible and reduced coinsurance created by the Consolidated Appropriations Act, 2021. Without it, the claim reads as an ordinary diagnostic procedure.
Only the more extensive endoscopy
CMS states that only the more extensive endoscopic procedure may be reported for a patient encounter -- if a sigmoidoscopy is completed and the physician then performs a colonoscopy, only the colonoscopy is reported. Where an endoscopy is converted to an open procedure, only the open procedure is reported.
What the endoscopy already includes
Control of bleeding during an endoscopic procedure is integral to it and is not separately reportable, unless a separate encounter on the same date requires a return. Fluoroscopy performed during an endoscopy is integral. Dilation codes are reported with one unit however many strictures were dilated in the procedure.
Denial and rejection risks
Gastroenterology's characteristic failure is not a denied claim -- it is a claim that pays and lands the cost on the wrong party.
A screening that became diagnostic, without PT
The claim adjudicates normally and the patient is billed cost-sharing they should not have owed. Nothing rejects, nothing appears on a denial worklist, and the error surfaces as a patient complaint rather than as a remittance code.
Screening delivered inside the interval
Frequency limits in 42 CFR 410.37 are absolute for coverage purposes. A screening performed before the patient is eligible again is not payable as a screening, and high-risk status has to be supported by the record rather than asserted on the claim.
Unbundled endoscopic components
Reporting control of bleeding, fluoroscopy, or a lesser endoscopy alongside the more extensive one that included it produces bundling denials that are correct and not worth appealing.
Pathology units that do not match the specimens
A multi-polyp procedure generates several specimens. Surgical pathology is reported per specimen submitted, so units billed from the number of polyps rather than the number of containers will not reconcile.
Payer-process considerations
Colorectal cancer screening is one of the few areas where the coverage rule is federal statute and regulation rather than payer policy -- which makes the exceptions the thing to watch.
The statutory coinsurance phase-down
Section 122 of Division CC of the Consolidated Appropriations Act, 2021 created a reduced coinsurance for procedures added during a screening encounter, phasing down over a defined schedule until no coinsurance applies for services furnished from 2030 onward. It is a statutory entitlement, not a plan concession.
A complete colorectal cancer screening
Since the CY 2023 Physician Fee Schedule final rule, a follow-on screening colonoscopy after a covered non-invasive stool-based test returns a positive result is itself part of the screening rather than a diagnostic procedure. CMS made the change explicitly to remove the cost-sharing barrier to completing the screening.
Regulated intervals and the age floor
42 CFR 410.37 fixes the minimum age -- reduced to 45 -- and the intervals for each screening test, including how a prior flexible sigmoidoscopy or colonoscopy affects when the next is payable. These are conditions of coverage, not utilization-management preferences.
Commercial and Medicare Advantage variation
Commercial plans administer preventive colorectal screening under their own rules and commonly use a different preventive-service modifier, and Medicare Advantage plans layer prior authorization and site-of-care direction on top of the Medicare benefit. The federal rule sets the floor, not the whole picture.
Revenue-cycle checkpoints
Nearly every one of these happens before the patient is sedated, which is what makes them worth building a process around.
- Record the procedure's intent -- screening, surveillance or diagnostic -- on the order, in a field the claim can read
- Confirm the screening interval and, where claimed, that the record supports high-risk status
- Have the screening-becomes-diagnostic conversation with the patient before the procedure, not after the bill
- Append modifier PT on every claim where a screening colorectal procedure became diagnostic or therapeutic
- Report only the more extensive endoscopic procedure performed at the encounter
- Match surgical pathology units to specimen containers rather than to the number of lesions removed
- Check the remittance to confirm the reduced cost-sharing was actually applied where PT was reported
Related & connected
Services, tools, background reading and definitions that connect to the gastroenterology revenue-cycle steps above.
Related services
- Coding supportEndoscopic code selection, modifier PT, and keeping integral services off the claim.
- Eligibility & verificationConfirming screening intervals, risk status and authorization before a scheduled procedure.
- Patient billing & supportExplaining a balance on a procedure the patient understood to be a free preventive screening.
Calculators & tools
- Medicare claim readiness checklistWork through what a Medicare claim needs before submission in a Medicare-weighted specialty.
- Clean claim submission readinessConfirm a professional claim is complete before release, including modifiers that change cost-sharing.
- Denial rate calculatorSize how often claims are denied so bundling and eligibility issues can be prioritized.
From the Knowledge Base
- Medicare preventive services billingHow Medicare's preventive benefits are structured, and what changes when a preventive service is not purely preventive.
- Patient responsibilityDeductibles, copays and coinsurance -- the amounts modifier PT exists to protect a screening patient from.
- Partial denialsWhen part of a claim pays and part does not, which is how bundled endoscopic lines usually surface.
Glossary
- CoinsuranceThe share of an allowed amount a patient owes, and the thing the screening rule reduces.
- DeductibleThe amount a patient pays before coverage begins, waived on a screening that becomes diagnostic.
- Covered serviceWhether a plan pays for a service at all, as distinct from whether it was clinically appropriate.
- National Coverage DeterminationThe national policy instrument that, with 42 CFR 410.37, defines colorectal cancer screening coverage.
Frequently asked questions
Why does a free screening colonoscopy sometimes produce a bill?
Because the procedure changed. A colonoscopy scheduled as a preventive screening in which a polyp is found and removed is no longer a screening -- it is a therapeutic procedure, reported with the code that describes what was done. Congress addressed the consequence rather than the coding: where modifier PT records that the service began as a screening, the deductible is waived and the coinsurance is reduced, phasing down until no coinsurance applies for services furnished from 2030 onward.
What does modifier PT do?
It tells the payer that a colorectal cancer screening test became a diagnostic or therapeutic service. It does not change the procedure code -- the claim still reports what was actually performed -- but it carries the fact that the encounter started as a screening, which is what triggers the reduced patient cost-sharing. Omitting it produces a claim that pays normally and bills the patient in full.
Is a colonoscopy after a positive stool-based test a screening or a diagnostic procedure?
Under Medicare it is now part of the screening. CMS explained in the CY 2023 Physician Fee Schedule final rule that it had historically treated a colonoscopy following a positive non-invasive stool-based test as diagnostic, and expanded the regulatory definition so that the two together form a complete colorectal cancer screening -- specifically to remove the cost-sharing barrier to finishing it.
If a sigmoidoscopy and a colonoscopy are both performed, can both be billed?
No. CMS states that only the more extensive endoscopic procedure may be reported for a patient encounter, so a completed sigmoidoscopy followed by a colonoscopy in the same session is reported as a colonoscopy. The same principle applies when an endoscopy is converted to an open procedure -- only the open procedure is reported.
Sources
Last reviewed July 31, 2026.
- Electronic Code of Federal Regulations (eCFR)42 CFR 410.37 -- colorectal cancer screening tests: conditions for and limitations on coverage, including high-risk definitions and screening intervals
- Centers for Medicare & Medicaid Services (CMS)MLN Matters MM12656 -- changes to beneficiary coinsurance for procedures furnished during the same clinical encounter as certain colorectal cancer screening tests, and the modifier PT rule
- Federal Register (Centers for Medicare & Medicaid Services)CY 2023 Physician Fee Schedule final rule -- expansion of coverage for colorectal cancer screening and the complete-screening definition
- Centers for Medicare & Medicaid Services (CMS)National Correct Coding Initiative Policy Manual, Chapter VI (Surgery: Digestive System) -- endoscopy reporting, integral services and units of service
- American College of Gastroenterology (ACG)Practice-management and coding guidance for gastroenterology
Ready to improve your revenue cycle?
Tell us about your practice and we’ll tell you where we would start.